Plasma phosphorylated tau (p‐tau), particularly p‐tau217, is a highly specific biomarker of Alzheimer's disease (AD) pathology. However, plasma p‐tau217 can be elevated in rare non‐AD conditions. Brain‐derived (BD) p‐tau217 may reduce these off‐target effects, but its performance against neuropathology has not been eva...
Marisa N. Denkinger, W. Brum, A. Leuzy et al.· Alzheimer's & Dementia· 0 citations
This multicohort study demonstrated how including additional plasma proteins significantly enhanced the performance of p-tau217 in predicting advanced tau pathology among amyloid-positive individuals, suggesting a multiprotein approach may offer a viable and scalable alternative to tau PET staging in clinical or resear...
Guglielmo di Molfetta, W. Brum, I. Pola et al.· JAMA Neurology· 1 citation
Whether these proteins, alone or combined with plasma phosphorylated tau 217 (p‐tau217), predict progression from cognitively unimpaired to symptomatic AD is evaluated.